Glutamatergic Modulation of Auditory Information Processing in the Human Brain

BACKGROUND Auditory mismatch negativity (MMN) and P300 event-related potentials (ERPs) are reduced in schizophrenia patients and healthy volunteers administered the N-methyl-D-aspartate glutamate receptor antagonist, ketamine. In rodents, N-acetylcysteine (NAC), a stimulator of the cystine-glutamate exchanger, attenuates the cognitive and behavioral effects of N-methyl-D-aspartate receptor antagonists. On the basis of these findings, we tested whether NAC would reduce ketamine effects on behavior, MMN, and P300 in healthy humans. METHODS This randomized, double-blind, placebo-controlled study consisted of 2 test days during which subjects (n = 16) were administered oral NAC (3000 mg in divided doses) or matching placebo 165 min before the infusion of saline and then ketamine (as a bolus of .23 mg/kg over 1 min followed by .58 mg/kg for 30 min, and then .29 mg/kg for 40 min) in a fixed order. Behavioral and ERP data including auditory MMN and P300 were collected during each test day. RESULTS Ketamine produced psychotic-like positive symptoms, reductions in working memory and sustained attention performance, and amplitude reductions for the frequency- and intensity-deviant MMNs and P300. NAC pretreatment did not reduce the behavioral or ERP effects of ketamine. In addition, NAC reduced frequency-deviant MMN amplitude and increased target and novelty P3 amplitudes. The decrements in frequency-deviant MMN amplitude produced by ketamine and NAC were not additive. CONCLUSIONS NAC did not attenuate the effects of ketamine in humans, in contrast to previous studies in animals. NAC merits further investigation as a cognitive enhancing agent due to its ability to increase the P300 amplitude.

[1]  R. Johnson.  A triarchic model of P300 amplitude. , 1986, Psychophysiology.

[2]  Ulrich Schall,et al.  Functional neuroanatomy of auditory mismatch processing: an event-related fMRI study of duration-deviant oddballs , 2003, NeuroImage.

[3]  A. Abi-Dargham,et al.  Imaging Changes in Glutamate Transmission In Vivo with the Metabotropic Glutamate Receptor 5 Tracer [11C] ABP688 and N-Acetylcysteine Challenge , 2011, Biological Psychiatry.

[4]  C. Schroeder,et al.  Role of cortical N-methyl-D-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[5]  R. Näätänen.  The Mismatch Negativity: A Powerful Tool for Cognitive Neuroscience , 1995, Ear and hearing.

[6]  T. Murphy,et al.  Immature cortical neurons are uniquely sensitive to glutamate toxicity by inhibition of cystine uptake , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  P. Michie,et al.  Duration and frequency mismatch negativity in schizophrenia , 2000, Clinical Neurophysiology.

[8]  C. Schroeder,et al.  Detection of stimulus deviance within primate primary auditory cortex: intracortical mechanisms of mismatch negativity (MMN) generation , 1994, Brain Research.

[9]  D. Schoepp.  Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. , 2001, The Journal of pharmacology and experimental therapeutics.

[10]  P Boesiger,et al.  Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo , 2000, The European journal of neuroscience.

[11]  John H Krystal,et al.  Modulation of the cortical processing of novel and target stimuli by drugs affecting glutamate and GABA neurotransmission. , 2009, The international journal of neuropsychopharmacology.

[12]  Ruben C Gur,et al.  Neurocognition in schizophrenia. , 2010, Current topics in behavioral neurosciences.

[13]  H. Yabe,et al.  Deviant Matters: Duration, Frequency, and Intensity Deviants Reveal Different Patterns of Mismatch Negativity Reduction in Early and Late Schizophrenia , 2008, Biological Psychiatry.

[14]  R. Anwyl,et al.  Presynaptic inhibitory action of the group II metabotropic glutamate receptor agonists, LY354740 and DCG-IV. , 1998, European journal of pharmacology.

[15]  Herbert Weingartner,et al.  NMDA Receptor Function and Human Cognition: The Effects of Ketamine in Healthy Volunteers , 1996, Neuropsychopharmacology.

[16]  P. Rabbitt,et al.  Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. , 1994, Dementia.

[17]  J. Polich.  P300 from a passive auditory paradigm. , 1989, Electroencephalography and clinical neurophysiology.

[18]  B. Turetsky,et al.  P300 subcomponent abnormalities in schizophrenia: I. Physiological evidence for gender and subtype specific differences in regional pathology , 1998, Biological Psychiatry.

[19]  H. Westenberg,et al.  No effects of l-dopa and bromocriptine on psychophysiological parameters of human selective attention , 2006, Journal of psychopharmacology.

[20]  R. Knight,et al.  Neural origins of the P300. , 2000, Critical reviews in neurobiology.

[21]  D. Cyril D’Souza,et al.  Interactive effects of subanesthetic ketamine and haloperidol in healthy humans , 1999, Psychopharmacology.

[22]  Reto Meuli,et al.  Glutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients , 2008, Neuropsychopharmacology.

[23]  C. C. Duncan,et al.  Event-related brain potentials: a window on information processing in schizophrenia. , 1988, Schizophrenia bulletin.

[24]  K. Phan,et al.  Acute dopamine and/or serotonin depletion does not modulate mismatch negativity (MMN) in healthy human participants , 2010, Psychopharmacology.

[25]  D. Friedman,et al.  The novelty P3: an event-related brain potential (ERP) sign of the brain's evaluation of novelty , 2001, Neuroscience & Biobehavioral Reviews.

[26]  Bob Oranje,et al.  Haloperidol counteracts the ketamine-induced disruption of processing negativity, but not that of the P300 amplitude. , 2009, The international journal of neuropsychopharmacology.

[27]  A. Carlsson,et al.  Network interactions in schizophrenia — therapeutic implications , 2000, Brain Research Reviews.

[28]  A. Belger,et al.  Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. , 2005, Archives of general psychiatry.

[29]  E Donchin,et al.  The P300 as a metric for mental workload. , 1987, Electroencephalography and clinical neurophysiology. Supplement.

[30]  L. Opler,et al.  The Positive and Negative Syndrome Scale (PANSS): Rationale and Standardisation , 1989, British Journal of Psychiatry.

[31]  Edgar Brunner,et al.  Nonparametric analysis of longitudinal data in factorial experiments , 2012 .

[32]  E. Donchin,et al.  P300 and tracking difficulty: evidence for multiple resources in dual-task performance. , 1980, Psychophysiology.

[33]  R. Näätänen,et al.  The mismatch negativity (MMN): towards the optimal paradigm , 2004, Clinical Neurophysiology.

[34]  E. John,et al.  Evoked-Potential Correlates of Stimulus Uncertainty , 1965, Science.

[35]  A. Dickinson,et al.  Frontal responses during learning predict vulnerability to the psychotogenic effects of ketamine: linking cognition, brain activity, and psychosis. , 2006, Archives of general psychiatry.

[36]  J. Ford,et al.  ERPs in schizophrenia: Effects of antipsychotic medication , 1994, Biological Psychiatry.

[37]  N. Squires,et al.  Two varieties of long-latency positive waves evoked by unpredictable auditory stimuli in man. , 1975, Electroencephalography and clinical neurophysiology.

[38]  M. Cuénod,et al.  N-Acetyl Cysteine as a Glutathione Precursor for Schizophrenia—A Double-Blind, Randomized, Placebo-Controlled Trial , 2008, Biological Psychiatry.

[39]  S. Kapur,et al.  NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D2 and serotonin 5-HT2 receptors—implications for models of schizophrenia , 2002, Molecular Psychiatry.

[40]  Adolf Pfefferbaum,et al.  Trait and state aspects of p300 amplitude reduction in schizophrenia: a retrospective longitudinal study , 2000, Biological Psychiatry.

[41]  H. de Wit,et al.  Acute effects of d-amphetamine during the follicular and luteal phases of the menstrual cycle in women , 1999, Psychopharmacology.

[42]  E. Halgren,et al.  The intracranial topography of the P3 event-related potential elicited during auditory oddball. , 1990, Electroencephalography and clinical neurophysiology.

[43]  P. Michie,et al.  What has MMN revealed about the auditory system in schizophrenia? , 2001, International journal of psychophysiology : official journal of the International Organization of Psychophysiology.

[44]  J. Seamans,et al.  Cystine/Glutamate Exchange Regulates Metabotropic Glutamate Receptor Presynaptic Inhibition of Excitatory Transmission and Vulnerability to Cocaine Seeking , 2005, The Journal of Neuroscience.

[45]  Godfrey Pearlson,et al.  An adaptive reflexive processing model of neurocognitive function: supporting evidence from a large scale (n = 100) fMRI study of an auditory oddball task , 2005, NeuroImage.

[46]  S. Andrews,et al.  Mismatch negativity: An index of a preattentive processing deficit in schizophrenia , 1991, Biological Psychiatry.

[47]  V. Haroutunian,et al.  Contribution of Cystine–Glutamate Antiporters to the Psychotomimetic Effects of Phencyclidine , 2008, Neuropsychopharmacology.

[48]  E. Halgren,et al.  Generators of the late cognitive potentials in auditory and visual oddball tasks. , 1998, Electroencephalography and clinical neurophysiology.

[49]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[50]  M. Fabiani,et al.  Changes in brain activity patterns in aging: the novelty oddball. , 1995, Psychophysiology.

[51]  A. Belger,et al.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development , 2003, Psychopharmacology.

[52]  J. Polich,et al.  Meta-analysis of P300 and schizophrenia: patients, paradigms, and practical implications. , 2003, Psychophysiology.

[53]  M. Masu,et al.  Distribution of Cystine/Glutamate Exchange Transporter, System xc−, in the Mouse Brain , 2002, The Journal of Neuroscience.

[54]  V. Knott,et al.  Separate and combined effects of low dose ketamine and nicotine on behavioural and neural correlates of sustained attention , 2011, Biological Psychology.

[55]  T. Goldberg,et al.  Cognitive impairment in schizophrenia is the core of the disorder. , 2000, Critical reviews in neurobiology.

[56]  S. Southwick,et al.  Measurement of Dissociative States with the Clinician-Administered Dissociative States Scale (CADSS) , 1998, Journal of traumatic stress.

[57]  J. Newcomer,et al.  NMDA receptor hypofunction model of schizophrenia. , 1999, Journal of psychiatric research.

[58]  J. Polich.  Updating P300: An integrative theory of P3a and P3b , 2007, Clinical Neurophysiology.

[59]  A. Muzet,et al.  Electroencephalographic Characterization of Brain Dopaminergic Stimulation by Apomorphine in Healthy Volunteers , 1999, Neuropsychobiology.

[60]  P. Michie,et al.  Association between reduced duration mismatch negativity (MMN) and raised temporal discrimination thresholds in schizophrenia , 2003, Clinical Neurophysiology.

[61]  D. Javitt,et al.  Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. , 2000, Archives of general psychiatry.

[62]  M. Ikeda,et al.  Oxidative neuronal death caused by glutamate uptake inhibition in cultured hippocampal neurons , 2003, Journal of neuroscience research.

[63]  D. Hatsukami,et al.  Sex and menstrual cycle differences in the subjective effects from smoked cocaine in humans. , 1999, Experimental and clinical psychopharmacology.

[64]  D. Schubert,et al.  Distribution of the Cystine/Glutamate Antiporter System x− c in the Brain, Kidney, and Duodenum , 2006, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[65]  B. Moghaddam,et al.  Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. , 1998, Science.

[66]  D. Linden.  The P300: Where in the Brain Is It Produced and What Does It Tell Us? , 2005, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[67]  R. Kikinis,et al.  Increased rate of P300 latency prolongation with age in schizophrenia. Electrophysiological evidence for a neurodegenerative process. , 1995, Archives of general psychiatry.

[68]  M. Keshavan,et al.  Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. , 2011, Antioxidants & redox signaling.

[69]  H. Gunduz-Bruce,et al.  The acute effects of NMDA antagonism: From the rodent to the human brain , 2009, Brain Research Reviews.

[70]  J. Krystal,et al.  γ-Aminobutyric Acid–Serotonin Interactions in Healthy Men: Implications for Network Models of Psychosis and Dissociation , 2006, Biological Psychiatry.

[71]  E. Donchin,et al.  On quantifying surprise: the variation of event-related potentials with subjective probability. , 1977, Psychophysiology.

[72]  Zheng-Xiong Xi,et al.  The Origin and Neuronal Function of In Vivo Nonsynaptic Glutamate , 2002, The Journal of Neuroscience.

[73]  Bob Oranje,et al.  The Effects of a Sub-Anaesthetic Dose of Ketamine on Human Selective Attention , 2000, Neuropsychopharmacology.

[74]  D. Umbricht,et al.  Mismatch negativity in schizophrenia: a meta-analysis , 2005, Schizophrenia Research.

[75]  Ray Johnson.  For Distinguished Early Career Contribution to Psychophysiology: Award Address, 1985 , 1986 .

[76]  E R John,et al.  Information Delivery and the Sensory Evoked Potential , 1967, Science.